News

Video

Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial

Author(s):

Nizar M. Tannir, MD, FACP

Nizar Tannir, MD, FACP, presents extended follow-up data assessing the combination of nivolumab and ipilimumab compared with sunitinib in the frontline setting of patients with advanced renal cell carcinoma (RCC).

Related Videos
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Chad Tang, MD
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Lorenza Rimassa, MD
Martin H. Voss, MD
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Martin H. Voss, MD
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Related Content
Wenxin “Vincent” Xu, MD
October 25th 2024

Immunotherapy Combinations Dominate Frontline Discussions in Advanced RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Chad Tang, MD
October 15th 2024

Prospective Trials Could Refine Potential Roles for Radiation in Advanced RCC

Neal Shore, MD, FACS
January 26th 2023

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute
October 2nd 2024

Repeat Immune Checkpoint Inhibitor Therapy Not Recommended for Advanced Kidney Cancer

Saby George, MD, FACP, Professor, Oncology and Medicine, Director, Network Clinical Trials, Roswell Park
October 1st 2024

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer